Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Hans Gelderblom, Robin L. Jones, Jean Yves Blay, Suzanne George, Margaret von Mehren, John R. Zalcberg, Yoon Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Brittany L. Siontis, David Goldstein, Kjetil Boye, Cesar Sanchez, Neeltje Steeghs, Piotr Rutkowski, Mihaela Druta, César Serrano, Neeta SomaiahPing Chi, Brooke Harrow, Claus Becker, William Reichmann, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michael C. Heinrich, Sebastian Bauer

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study'. Together they form a unique fingerprint.

Medicine & Life Sciences